Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: Results from capsure

Journal of Urology

Volumn 170, Issue 5, 2003, Pages 1804-1807

  Harlan, Susan R ^a   Cooperberg, Matthew R ^a   Elkin, Eric P ^a   Lubeck, Deborah P ^a   Meng, Maxwell V ^a   Mehta, Shilpa S ^b   Carroll, Peter R ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TAP PHARMACEUTICAL PRODUCTS INC   (United States)

^c Box 0738 ^*  (United States)

Author keywords

Prostatic neoplasms; Therapy; Trends

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER REGISTRY; CANCER RISK; CANCER STAGING; CHI SQUARE TEST; CLINICAL FEATURE; CLINICAL PROTOCOL; COMORBIDITY; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DEMOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATIENT CARE; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SOCIAL STATUS; TECHNIQUE;

EID: 0141919735     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000091641.34674.11     Document Type: Article

References (19)

1. Quinlan, D. M., Partin, A. W. and Walsh, P. C.: Can aggressive prostatic carcinomas be identified and can their natural history be altered by treatment? Urology, 46: 77, 1995
2. Steinberg, G. D., Bales, G. T. and Brendler, C. B.: An analysis of watchful waiting for clinically localized prostate cancer. J Urol, 159: 1431, 1998
3. Wei, J. T., Dunn, R. L., Sandler, H. M., McLaughlin, P. W., Montie, J. E., Litwin, M. S. et al: Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol, 20: 557, 2002
4. Albertsen, P. C., Hanley, J. A., Gleason, D. F. and Barry, M. J.: Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA, 280: 975, 1998
5. Johansson, J. E., Holmberg, L., Johansson, S., Bergstrom, R. and Adami, H. O.: Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA, 277: 467, 1997
6. Carter, H. B., Walsh, P. C., Landis, P. and Epstein, J. I.: Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol, 167: 1231, 2002
7. Choo, R., Klotz, L., Danjoux, C., Morton, G. C., DeBoer, G., Szumacher, E. et al: Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol, 167: 1664, 2002
8. Koppie, T. M., Grossfeld, G. D., Miller, D., Yu, J., Stier, D., Broering, J. M. et al: Patterns of treatment of patients with prostate cancer initially managed with surveillance: results from the CaPSURE database. J Urol, 164: 81, 2000
9. Lubeck, D. P., Litwin, M. S., Henning, J. M., Stier, D. M., Mazonson, P., Fisk, R. et al: The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology, 48: 773, 1996
10. D'Amico, A. V., Whittington, R., Malkowicz, S. B., Schultz, D., Blank, K., Broderick, G. A. et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA, 280: 969, 1998
11. Choo, R., DeBoer, G., Klotz, L., Danjoux, C., Morton, G. C., Rakovitch, E. et al: PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys, 50: 615, 2001
12. Holmberg, L., Bill-Axelson, A., Helgesen, F., Salo, J. O., Folmerz, P., Haggman, M. et al: A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med, 347: 781, 2002
13. Wilt, T. J. and Brawer, M. K.: The Prostate Cancer Intervention Versus Observation Trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. J Urol, 152: 1910, 1994
14. Zietman, A. L., Thakral, H., Wilson, L. and Schellhammer, P.: Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. J Urol, 166: 1702, 2001
15. Derksen, J. E., Kshirsagar, A. V. and Mohler, J. L.: Psychological consequences of observation versus radical prostatectomy for clinically localized prostate cancer three and ten years later. J Urol, suppl., 167: 340, abstract 1347, 2002
16. Ung, J. O., Richie, J. P., Chen, M. H., Renshaw, A. A. and D'Amico, A. V.: Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology, 60: 458, 2002
17. Cooperberg, M. R., Lubeck, D. P., Mehta, S. S. and Carroll, P. R.: Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). Unpublished data
18. Cooperberg, M. R., Mehta, S. S., Lubeck, D. P., Meng, M. V. and Carroll, P. R.: The changing face of low-risk prostate cancer: trends in clinical presentation and treatment patterns (data from CaPSURE). J Urol, suppl., 169: 459, abstract 1723, 2003
19. Etzioni, R., Penson, D. F., Legler, J. M., di Tommaso, D., Boer, R., Gann, P. H. et al: Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst, 94: 981, 2002